Takashi Ozawa
ABSTRACT
Artificial creation of fibers utilizing proteins has been a target of bionanotechnology. Yagi et al. succeeded in designing artificial protein fibers using two types of proteins: LARFH and sulerythrin. Binding interfaces were designed for sulerythrin and LARFH by introducing mutations, and the fibrous structures were confirmed by atomic force microscopy. However, branching was observed in the fibrous structure, possibly because of non-specific interactions between the proteins. In this study, we analyzed the behavior and binding sites of sulerythrin mutants and LARFH mutants using coarse-grained molecular dynamics (MD) simulation. Binding simulations were performed for a system of one sulerythrin and one LARFH, and also of two sulerythrin molecules and four LARFH molecules. These results suggested that glutamic acids originally possessed by sulerythrin contribute to non-specific binding at sites other than the designed interfaces.
- Grueninger, D., Treiber, N., Ziegler, M. O., Koetter, J. W., Schulze, M. S., and Schulz, G. E. 2008. Designed protein-protein association. Science 319 (Jan. 2008), 206--209.Google Scholar
Cross Ref
- Padilla, J. E., Colovos, C., and Yeates, T. O. 2001. Nanohedra: Using symmetry to design self assembling protein cages, layers, crystals, and filaments. P. Natl. Acad. Sci. USA 98 (Feb. 2001), 2217--2221.Google ScholarCross Ref
- King, N. P., Bale, J. B., Sheffler, W., McNamara, D. E., Gonen, S., Gonen, T., Yeates, T. O., and Baker, D. 2014. Accurate design of co-assembling multi-component protein nanomaterials, Nature 510 (May 2014), 103--108.Google ScholarCross Ref
- Karanicolas, J., Corn, J. E., Chen, I., Joachimiak, L. A., Dym, O., Peck, S. H., Albeck, S., Unger, T., Hu, W., Liu, G., Delbecq, S., Montelione, G. T., Spiegel, C. P., Liu, D. R., and Baker, D. 2011. A de novo protein binding pair by computational design and directed evolution. Mol. Cell. 42 (Apr. 2011), 250--260.Google ScholarCross Ref
- Yagi, S., Akanuma, S., and Yamagishi, A. 2014. Addition of negatively charged residues can reverse the decrease in the solubility of an acidic protein caused by an artificially introduced non-polar surface patch. Biochim. Biophys. Acta. 1844 (Mar. 2014), 553--560.Google ScholarCross Ref
- Akanuma, S., Matsuba, T., Ueno, E., Umeda, N., and Yamagishi, A. 2010. Mimicking the evolution of a thermally stable monomeric four-helix bundle by fusion of four identical single- helix peptides. J. Biochem. 147 (Mar. 2010), 371--379.Google ScholarCross Ref
- Yagi, S., Akanuma, S., Yamagishi, M., Uchida, T., and Yamagishi, A. 2016. De novo design of protein--protein interactions through modification of inter-molecular helix--helix interface residues. Biochim. Biophys. Acta 1864 (May 2016), 479--487.Google ScholarCross Ref
- Guex, N. and Peitsch, M. C. 1997. SWISS-MODEL and the Swiss-Pdb Viewer: An environment for comparative protein modeling. Electrophoresis 18 (1997), 2714--2723.Google ScholarCross Ref
- Berendsen, H. J. C., van der Spoel, D., and van Drunen, R. 1995. GROMACS: A message-passing parallel molecular dynamics implementation. Comp. Phys. Comm. 91 (Sept. 1995) 43--56.Google Scholar
- Lindahl, E., Hess, B., and van der Spoel, D. 2001. GROMACS 3.0: package for molecular simulation and trajectory analysis. J. Mol. Model. 7 (Aug. 2001), 306--317.Google Scholar
- van der Spoel, D., Lindahl, E., Hess, B., Groenhof, G., Mark, A. E., Berendsen, H. J. C. 2005. GROMACS: Fast, flexible, and free. J. Comput. Chem 26 (Oct. 2005) 1701--1718.Google Scholar
- Hess, B., Kutzner, C., van der Spoel, D., Lindahl, E. 2008. GROMACS 4: Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular simulation. J. Chem. Theory Comput. 4 (Feb. 2008), 435--447.Google Scholar
- Pronk, S., Páll, S., Schulz, R., Larsson, P., Bjelkmar, P., Apostolov, R., Shirts, M. R., Smith, J. C., Kasson, P., M., van der Spoel, D., Hess, B., and Lindahl, E. 2013. GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics 29 (Apr. 2013), 845--854. Google ScholarDigital Library
- Szilárd, P., Abraham, M. J., Kutzner, C., Hess, B., and Lindahl, E. 2015. Tacking Exascale Software Challenges in Molecular Dynamics Simulations with GROMACS. Proc. of EASC 2015 LNCS, 8759 (Feb. 2015), 3--27.Google Scholar
- Abraham, J. M., Murtola, T., Schulz, R., Páll, S., Smith, J. C., Hess, B., and Lindahl, E. 2015. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1-2 (Sept. 2015), 19--25.Google ScholarCross Ref
- Monticelli, L., Kandasamy, S. K., Periole, X., Larson, R. G., Tieleman, D. P., and Marrink, S. J. 2008. The MARTINI coarse-grained force field: extension to proteins. J. Chem. Comput. 4 (Apr. 2008), 819--834.Google Scholar
- Marrink, S. J., Risselada, H. J., Yefimov, S., Tielema, D. P., and Vries, A. H. 2007. The MARTINI Force Field: Coarse Grained Model for Biomolecular Simulations. J. Phys. Chem. 111 (June 2007), 7812--7824.Google ScholarCross Ref
Index Terms
- Coarse-Grained Molecular Dynamics Simulation of Sulerythrin and LARFH for Producing Protein Nanofibers
Recommendations
Homology modeling and molecular dynamic simulation of UDP-N-acetylmuramoyl-l-alanine-d-glutamate ligase (MurD) from Mycobacterium tuberculosis H37Rv using in silico approach
Graphical abstractDisplay Omitted
AbstractThe present study aimed to identify the prospective inhibitors of MurD, a cytoplasmic enzyme that catalyzes the addition of d-glutamate to the UDP-N-acetylmuramoyl-l-alanine nucleotide precursor in Mycobacterium tuberculosis (MTB), ...
A multidrug efflux protein in Mycobacterium tuberculosis; tap as a potential drug target for drug repurposing
AbstractTuberculosis (TB) is a serious communicative disease caused by Mycobacterium tuberculosis. Although there are vaccines and drugs available to treat the disease, they are not efficient, moreover, multidrug-resistant ...
Graphical abstractDisplay Omitted
Highlights- Tuberculosis (TB) is a serious communicative disease caused by M. tuberculosis.
Benchmarking the ability of novel compounds to inhibit SARS-CoV-2 main protease using steered molecular dynamics simulations
Abstract BackgroundThe SARS-CoV-2 main protease (Mpro) is an attractive target in the COVID-19 drug development process. It catalyzes the polyprotein's translation from viral RNA and specifies a particular cleavage site. Due to the ...
Graphical abstractDisplay Omitted
Highlights- Molecule 3h interacted with catalytic dyad residues Cys145 and His41 of SARS-CoV-2 main protease.
Comments